MARKET NEWS

Immutep Granted New Patents for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
Ocuphire Pharma Enters Global License Agreement for Development & Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia & Night Vision Disturbances
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
SomaLogic Teams With Molecular Genomics to Bring the 7,000-Plex SomaScan Platform to Asia
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
Actym Therapeutics Reports Preclinical Data Demonstrating Ability to Generate Anti-Tumor Immunity

  FEATURED EDITORIAL

  COMPANY PROFILE

LATITUDE’s formulation scientists overcome the challenges of difficult compounds, and are the foundation of LATITUDE’s reputation for creative approaches, reliability, transparency, rapid turnaround, and client satisfaction. LATITUDE’s extensive experience and technical strengths in a wide range of dosage forms are applied to help our clients successfully address even the most difficult formulation challenges including solubility, instability, bioavailability and in vivo adverse reactions. LATITUDE scientists have particular expertise in the formulation of complex injectables including nanoemulsions, liposomes, microspheres and nanoparticles. Click here for more.

  EXCLUSIVE ONLINE CONTENT

IMUNON Enters Technology Evaluation Agreement With Acuitas to Evaluate Placcine Plasmid DNA With Lipid Nanoparticle Delivery System

IMUNON Enters Technology Evaluation Agreement With Acuitas to Evaluate Placcine Plasmid DNA With Lipid Nanoparticle Delivery System

Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA and protein vaccines….

Minoryx & Neuraxpharm Announce Strategic Alliance to Provide New Therapy for Rare CNS Disease 

Minoryx & Neuraxpharm Announce Strategic Alliance to Provide New Therapy for Rare CNS Disease 

The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD)….

Insilico Medicine Signs Strategic Research Collaboration With Sanofi Worth up to .2 Billion

Insilico Medicine Signs Strategic Research Collaboration With Sanofi Worth up to $1.2 Billion

Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 targets, and additional R&D and sales milestones plus tier-based mid-single to low double-digit royalties….

GHO Capital & The Vistria Group to Acquire Alcami From Madison Dearborn Partners & Ampersand Capital Partners

GHO Capital & The Vistria Group to Acquire Alcami From Madison Dearborn Partners & Ampersand Capital Partners

Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, and The Vistria Group, a middle-market private investment firm focused on delivering financial returns and societal impact, recently….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

WHITEPAPER WORKSHOP - Soft Mist Inhalers

WHITEPAPER WORKSHOP - Soft Mist Inhalers

Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition.

The Resyca® SMI is a joint venture between Recipharm and Medspray that harnesses …

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

Manufacturing Phase 1 clinical material in as little as 12–16 months

Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 30 – Formulation Development
December 7 – Drug Delivery